
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is poised for success with its promising drug pipeline and strategic collaborations. The potential for FDA approval for vopimetostat in 2026 and the possibility of moving into first-line treatment ahead of a competitor's drug positions TNGX to capture a significant market share in the treatment of pancreatic and glioblastoma cancers. With a strong management team and promising preclinical data, the company has the potential to continue growing and delivering precision medicine for the treatment of cancer.
Bears say
Tango Therapeutics is likely to face challenges in the near future due to its heavy reliance on its pipeline products, particularly its PRMT5 and CoREST inhibitors. These products are still in the early stages of development and have not yet shown significant clinical success. Additionally, competition from other biotech companies, such as AZN, may hinder Tango's progress in the market. Combined with ongoing financial losses and the need for additional fundraising, it is likely that Tango's stock price will continue to be negatively affected in the short term.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares